2022 World Conference on Lung Cancer (ePosters)-EP08.01-004. Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab

EP08.01-004. Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab

Pdf Summary

This study analyzed the treatment patterns and outcomes of immunotherapy pretreated non-small cell lung cancer (NSCLC) patients who received pembrolizumab chemotherapy as a first-line treatment and subsequently developed progressive disease (PD). A retrospective analysis of the Glans-Look Lung Cancer Research database was conducted, including 140 NSCLC patients who experienced PD after receiving first-line pembrolizumab chemotherapy between 2017 and 2020. It was found that platinum-based chemotherapy doublet was the most common second-line (2L) treatment after pembrolizumab combination failure, while patients who continued the same immune checkpoint inhibitor treatment beyond PD had longer post-progression survival. Among patients with high PD-L1 expression, continuing pembrolizumab treatment was associated with longer survival compared to switching to platinum doublet chemotherapy for 2L treatment. The study also revealed that patients who received 2L treatment had a median time to discontinuation of 4 months, while those who continued the same immune checkpoint inhibitor treatment after PD had a median time to discontinuation of 10 months. Additionally, the overall survival from the start of first-line treatment was longer in patients who continued immune checkpoint inhibitor treatment post PD compared to those who switched to 2L treatment. The findings suggest that pembrolizumab monotherapy may be an effective option for patients with PD-L1 high NSCLC or may provide better benefits than pembrolizumab in combination with chemotherapy. Overall, the study provides insights into the treatment patterns and outcomes for NSCLC patients who have relapsed after receiving pembrolizumab chemotherapy as a first-line treatment.

Asset Subtitle

Anifat Elegbede

Meta Tag

Speaker Anifat Elegbede

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

immunotherapy

non-small cell lung cancer

NSCLC

pembrolizumab chemotherapy

progressive disease

retrospective analysis

platinum-based chemotherapy

immune checkpoint inhibitor

PD-L1 expression

overall survival